There are many instances where a business review or report of a company from an authorized body can make or break its reputation and progress. One of the many examples today regarding this is Kerrisdale Capital’s Sahm Adrangi and his assessment on Proteostasis Therapeutics, Inc.
The Stand of Kerrisdale On Proteostasis’ Growth
Kerrisdale believes that Proteostasis Therapeutics investigational product called cystic-fibrosis drug PTI-428 will not scale up to be an effective product and will most likely fail at its Phase 3 trials. There will be so many things that could define a drug product to its success, but for Kerrisdale, PTI-428’s progress will remain to be seen. It is also in the calculation of Kerrisdale that in Phase 2 of the study of the drug, it still doesn’t have enough of a sample size to define its true potential. The treatment groups’ results also don’t appear to be robust enough to offer an accurate data of the drug’s worth. It may look impressive at face value, but it still appears to have a lot of unanswered anomalies that could result in more bad outcomes.
Kerrisdale also even believes that Proteostasis is intentionally hiding the negative data points in their research under the rug to show the people that it is worth more than it is.
This goes without saying then that Proteostoasis Therapeutics, Inc. is given a short position by Kerrisdale Capital, and Kerrisdale will stand to benefit from the fall of its share price. You must also know that Kerrisdale Capital is a private investment manager that focuses on company’s fundamentals and long-term value. It has also built a reputation for focusing on special event-driven situations that could make or break a company’s progress and sustainability. Kerrisdale is also a member of the Financial Industry Regulatory Authority.
Sahm Adrangi Profile
Sahm Adrangi is the renowned Chief Investment Officer of Kerrisdale Capital. Before such position, he already built an outstanding reputation working for the finance group, Deutsche Bank. It was there that Sahm Adrangi helped structure a series of non-investment grade bank debt and bond that yield high results. He was also the man who established a leverage system for the buy-out financings of the bank.